5 Drug Manufacturers - Specialty & Generic companies within the Healthcare sector.
| Symbol | Company | Price | 1‑day | 1‑month |
|---|---|---|---|---|
| CRON | Cronos Group | $3.10 | +0.98% | +11.51% |
| TLRY | Tilray Brands | $4.57 | +2.93% | +4.10% |
| CGC | Canopy Growth | $0.9700 | +4.08% | -0.41% |
| ACB | Aurora Cannabis | $2.99 | +0.34% | +10.74% |
| OGI | Organigram Global | $0.9900 | +0.00% | +0.92% |
Generic manufacturers occupy the other side of the patent cliff: their opportunity begins when someone else's exclusivity ends. The product is chemically identical to the original by regulatory requirement, so there is nothing to compete on but price and reliability of supply, and margins compress steadily as each additional entrant is approved.
Specialty pharmaceutical companies sit between this and branded pharma, holding smaller protected products or reformulations that face less competition but also address smaller populations. Both groups carry litigation and regulatory exposure — patent challenges, manufacturing inspections and pricing investigations — that can be material relative to their earnings.
Want a full fundamental breakdown on one of these companies?
Generate a free reportPrices shown are end-of-session closing values from the most recent completed trading day and are refreshed periodically, not in real time. Sector and industry classifications follow the labels reported by our market data provider and can differ from other schemes. This page is informational and is not investment advice.